Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
Related Articles
COVID-19 mRNA-1273 Vaccine Safety: Adverse Events of Special Interest – Renal and Urology News
Researchers performed a large-scale safety review to identity adverse events of special interested associated with the COVID-19 mRNA-1273 vaccine.
Concomitant Use of SSRIs and Oral Anticoagulants Increases Major Bleeding Risk – Renal and Urology News
Researchers evaluated whether concomitant use of SSRIs and oral anticoagulants is associated with an increased risk for major bleeding in patients with atrial fibrillation.
Hemodialysis History Does Not Impact Peritoneal Dialysis Dropout – Renal and Urology News
Primary reasons for HD to PD switch include vascular access failure, patient preference, social issues, and cardiovascular disease
Standard-Dose DOAC Equally Efficacious as Low-Dose in AF – Renal and Urology News
A study was conducted to compare the safety and effectiveness of different DOAC dosage regimens in patients with AF, high bleeding risk, and low thrombosis…
Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant – Renal and Urology News
Patients with stromal-predominant tumors had the youngest age at diagnosis compared with other histologic subtypes
Prostate Cancer BCR Risk Lower With Neoadjuvant Docetaxel, ADT – Renal and Urology News
The role of neoadjuvant chemohormonal therapy in surgically treated high-risk prostate cancer has been controversial.
Federal Advisory Urges Health Providers to Enhance Cyber Defenses – Renal and Urology News
The average financial impact of a health care breach is now $11 million, which far exceeds the spending required to get proper security, cybersecurity specialist…
US to Partner With 50 Countries to Prevent Future Pandemics – Renal and Urology News
(HealthDay News) — The Biden Administration announced Tuesday that it will work with 50 nations worldwide to try to prevent global pandemics such as COVID-19,…
Enhertu Gets Accelerated Approval for HER2-Expressing Solid Tumors – Renal and Urology News
The approval was based on data from 3 clinical trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.
Worse Sepsis Outcomes Linked to Higher Pro- and Anti-Inflammatory Cytokine Levels – Renal and Urology News
Researchers identified inflammatory subgroups in sepsis and assessed their association with previously described transcriptomic subphenotypes.